MX2018001041A - Concentrado que contiene alprostadil. - Google Patents

Concentrado que contiene alprostadil.

Info

Publication number
MX2018001041A
MX2018001041A MX2018001041A MX2018001041A MX2018001041A MX 2018001041 A MX2018001041 A MX 2018001041A MX 2018001041 A MX2018001041 A MX 2018001041A MX 2018001041 A MX2018001041 A MX 2018001041A MX 2018001041 A MX2018001041 A MX 2018001041A
Authority
MX
Mexico
Prior art keywords
concentrate containing
alprostadil
pharmaceutically acceptable
organic solvent
acceptable organic
Prior art date
Application number
MX2018001041A
Other languages
English (en)
Inventor
HÄUSLER Franz
Hesse Ernst
Hansbauer Bernhard
Original Assignee
Gebro Holding Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gebro Holding Gmbh filed Critical Gebro Holding Gmbh
Publication of MX2018001041A publication Critical patent/MX2018001041A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a una composición farmacéutica líquida en forma de un concentrado para la preparación de una solución para infusión, que contiene, especialmente que está constituida por, alprostadil (prostaglandina E1) como principio activo, disuelto en un disolvente orgánico farmacéuticamente aceptable o en una mezcla de disolventes de al menos un disolvente orgánico farmacéuticamente aceptable y agua, para uso en el tratamiento de enfermedad arterial oclusiva periférica (EAOP) mediante infusión intrarterial (i.a.).
MX2018001041A 2015-07-27 2016-07-25 Concentrado que contiene alprostadil. MX2018001041A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ATA50664/2015A AT517555A1 (de) 2015-07-27 2015-07-27 Konzentrat enthaltend Alprostadil
PCT/AT2016/060019 WO2017015691A1 (de) 2015-07-27 2016-07-25 Konzentrat enthaltend alprostadil

Publications (1)

Publication Number Publication Date
MX2018001041A true MX2018001041A (es) 2018-06-07

Family

ID=56852016

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001041A MX2018001041A (es) 2015-07-27 2016-07-25 Concentrado que contiene alprostadil.

Country Status (8)

Country Link
EP (1) EP3328357B1 (es)
AR (1) AR105503A1 (es)
AT (1) AT517555A1 (es)
BR (1) BR112018000525A2 (es)
CO (1) CO2018000526A2 (es)
MX (1) MX2018001041A (es)
PE (1) PE20180606A1 (es)
WO (1) WO2017015691A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05864B1 (et) * 2021-12-22 2024-02-15 Aktsiaselts Kevelt 3-hüdroksütsüklopentoonitsüklit sisaldava ühendi kompositsioon ja meetod selle stabiliseerimiseks

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4309579C3 (de) * 1993-03-24 2000-01-27 Sanol Arznei Schwarz Gmbh Pharmazeutische Zusammensetzung in Form einer Packung

Also Published As

Publication number Publication date
WO2017015691A1 (de) 2017-02-02
EP3328357B1 (de) 2020-12-09
AR105503A1 (es) 2017-10-11
CO2018000526A2 (es) 2018-04-19
BR112018000525A2 (pt) 2018-09-18
AT517555A1 (de) 2017-02-15
PE20180606A1 (es) 2018-04-09
EP3328357A1 (de) 2018-06-06

Similar Documents

Publication Publication Date Title
WO2016134223A3 (en) Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
EA201791019A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
EA201790389A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
MX355267B (es) Análogos de carba-nucleósido 2´-sustituidos para tratamiento antivírico.
PH12015502539A1 (en) Cenicriviroc compositions and methods of making and using the same
EA201590058A1 (ru) Аналоги глюкагона
PH12018500576A1 (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
EP4360621A3 (en) Formulations of bendamustine
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
MX2017000183A (es) Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides.
WO2016100949A3 (en) Method and compositions for dissolving or solubilizing therapeutic agents
EA201691741A1 (ru) Фармацевтическая композиция
MD20180049A2 (ro) Compoziţie farmaceutică
MX2018001041A (es) Concentrado que contiene alprostadil.
EA201890788A1 (ru) Препараты оланзапина с замедленным высвобождением
MX2016009458A (es) Solucion alcoholica estable de alprostadilo.
MX2016013979A (es) Nuevas vias de administracion de insulina, analogos de insulina o derivados de insulina.
MX2018001042A (es) Concentrado que contiene alprostadil.
EA201892095A1 (ru) Циклические динуклеотидные соединения и способы их применения
IN2014MU01178A (es)
EA201690240A1 (ru) Новые соединения индазола и способ их получения
EA201500090A1 (ru) Фармацевтическая композиция, содержащая силденафила цитрат, и способ ее приготовления
CU20140150A7 (es) Proceso para producir solución de acetaminofén supersaturada inyectable de administración por la espina dorsal
IN2014MU01179A (es)
WO2016115442A3 (en) Therapeutic protein formulations